Advertisement

Hormones

, Volume 12, Issue 1, pp 93–100 | Cite as

Salivary Cortisol day curves in assessing glucocorticoid replacement therapy in Addison’s disease

  • Lisanne Smans
  • Eef Lentjes
  • Ad Hermus
  • Pierre Zelissen
Research paper
  • 1 Downloads

Abstract

OBJECTIVE

Patients with Addison’s disease require lifelong treatment with glucocorticoids. At present, no glucocorticoid replacement therapy (GRT) can exactly mimic normal physiology. As a consequence, under-and especially overtreatment can occur. Suboptimal GRT may lead to various side effects. The aim of this study was to investigate the use of salivary cortisol day curves (SCDC) in the individual adjustment of GRT in order to approach normal cortisol levels as closely as possible, reduce over-and underreplacement and study the short-term effects on quality of life (QoL).

DESIGN AND METHODS

Twenty patients with Addison’s disease were included in this prospective study. A SCDC was obtained and compared to normal controls; general and disease specific QoL-questionnaires were completed. Based on SCDC assessment of over-and undertreatment (calculated as duration (h) X magnitude (nmol/L) at different time points, glucocorticoid dose and regime were adjusted. After 4 weeks SCDC and QoL assessment were repeated and the effect of adjusting GRT was analysed. RESULTS At baseline, underreplacement was present in 3 and overreplacement in 18 patients; total calculated overreplacement was 32.8 h.nmol/L. Overreplacement decreased significantly to 13.3 h. nmol/L (p =0.005) after adjustment of GRT. Overreplacement was found particularly in the afternoon and evening. After reducing overreplacement in the evening, complaints about sleep disturbances significantly decreased.

CONCLUSIONS

Individual adjustment of GRT based on SCDC to approach normal cortisol concentrations during the day can reduce overreplacement, especially in the evening. This can lead to a reduction of sleep disturbances and fatigue in patients with Addison’s disease. A SCDC is a simple and patient-friendly tool for adjusting GRT and can be useful in the follow-up of patients with Addison’s disease.

Key words

Addison’s disease Glucocorticoid replacement therapy Quality of Life Salivary cortisol day curve 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Peacy SR, Guo CY, Robinson AM, et al, 1997 Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol 46: 255–261.CrossRefGoogle Scholar
  2. 2.
    Zelissen PMJ, Croughs RJ, van Rijk PP, Raymakers JA, 1994 Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison’s disease. Ann Intern Med 120: 207–210.CrossRefPubMedGoogle Scholar
  3. 3.
    Giordano R, Marzotti S, Balbo M, et al, 2009 Metabolic and cardiovascular profile in patients with Addison’s disease under conventional glucocorticoid replacement. J Endocrinol Invest 32: 917–923.CrossRefPubMedGoogle Scholar
  4. 4.
    Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G, 2006 Premature mortality in patients with Addison’s disease: a population-based study. J Clin Endocrinol Metab 91: 4849–4853.CrossRefPubMedGoogle Scholar
  5. 5.
    Bensing S, Brandt L, Tabaroi F, et al, 2008 Increased death risk and altered cancer incidence pattern in patients withisolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf) 69: 697–704.CrossRefGoogle Scholar
  6. 6.
    Lovas K, Havard Loge J, Eystein Husebye S, 2002 Subjective health status in Norwegian patients with Addison’s disease. Clin Endocrinol 56: 581–588.CrossRefGoogle Scholar
  7. 7.
    Howlett TA, 1997 An assessment of optimal hydrocortisone replacement therapy. ClinEndocrinol 46: 263–286.Google Scholar
  8. 8.
    Lewis JG, 2006 Steroid Analysis in saliva: An overview. Clin Biochem Rev 27: 139–146.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Gatti R, Antonelli G, Prearo M, Spinella P, Cappellin E, de Palo EF, 2009 Cortisol assays and diagnostic laboratory procedures in human biological fluids. Clin Biochem 42: 1205–1217.CrossRefPubMedGoogle Scholar
  10. 10.
    Chalder T, Berelowitz G, Pawlikowska T, et al, 1993 Development of a fatigue scale. J Psychosomatic res 37: 147–153.CrossRefGoogle Scholar
  11. 11.
    Bleicken B, Hahner S, Loeffler M, Ventz M, Allolio B, Quinkler M, 2008 Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol 159: 811–817.CrossRefPubMedGoogle Scholar
  12. 12.
    Goldberg DP, Hillier VF, 1979 A scaled version of the General Health Questionnaire. Psychol Med 9: 139–145.CrossRefPubMedGoogle Scholar
  13. 13.
    Lovas K, Giesdal CG, Christensen M, et al, 2009 Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone. Eur J Endocrinol 160: 993–1002.CrossRefPubMedGoogle Scholar
  14. 14.
    Crown A, Lightman S, 2005 Why is management of glucocorticoid deficiency still controversial: a review of the literature. Clinical Endocrinol 62: 1–10.CrossRefGoogle Scholar
  15. 15.
    Alt W, Rosenthal C, Hahner S, Allolio B, 2006 Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol 64: 384–389.Google Scholar
  16. 16.
    Aardal E, Holm A, 1995 Cortisol in saliva-Reference ranges and relation to cortisol inserum. Eur J Clin Chem Biochem 33: 927–932.Google Scholar
  17. 17.
    Wong V, Yan T, Donald A, Mclean M, 2004 Saliva and bloodspot cortisol: novel sampling methods to assess hydrocortisone replacement therapy in hypoadrenal patients. Clin Endocrinol 61: 131–137.CrossRefGoogle Scholar
  18. 18.
    Lovas K, Thorsen TE, Husebye ES, 2006 Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison’s disease. J Endocrinol Invest 29: 727–731.CrossRefPubMedGoogle Scholar
  19. 19.
    Lovas K, Husebye ES, Holstein F, Bjorvatn B, 2003 Sleep disturbances in patients withAddison’s disease. Eur J Endocrinol 148: 449–456.CrossRefPubMedGoogle Scholar
  20. 20.
    Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S, 2009 Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 161: 119–130.CrossRefPubMedGoogle Scholar
  21. 21.
    Lovas K, Husebye ES, 2007 Continuous subcutaneous hydrocortisone infusion in Addison’s disease. Eur J Endocrinol 157: 109–112.CrossRefPubMedGoogle Scholar
  22. 22.
    Debono M, Ghobadi C, Rostami-Hodjegan A, et al, 2009 Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 94: 1548–1554.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Johannsson G, Nilsson AG, Bergthorsdottir R, 2012 Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 97: 473–481.CrossRefPubMedGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2013

Authors and Affiliations

  • Lisanne Smans
    • 1
  • Eef Lentjes
    • 2
  • Ad Hermus
    • 3
  • Pierre Zelissen
    • 2
  1. 1.Department of Internal Medicine and EndocrinologyUniversity Medical Center UtrechtUtrechtThe Netherlands
  2. 2.Laboratory of EndocrinologyUniversity Medical Center UtrechtUtrechtThe Netherlands
  3. 3.Department of EndocrinologyRadboud University Nijmegne Medical CenterNijmegneThe Netherlands

Personalised recommendations